2. Academic Validation
  3. Current Development Status of MEK Inhibitors

Current Development Status of MEK Inhibitors

  • Molecules. 2017 Sep 26;22(10):1551. doi: 10.3390/molecules22101551.
Ying Cheng 1,  Hongqi Tian 2
Affiliations

Affiliations

  • 1 Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300192, China. [email protected].
  • 2 Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300192, China. [email protected].
PMID: 28954413 DOI: 10.3390/molecules22101551
Abstract

The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may provide different options for patients seeking treatment for Cancer. Moreover, the combination of the MEK inhibitors with other therapies-such as chemotherapy, targeted therapy, and immunotherapy-may be a promising approach for clinical use.

Keywords

MEK inhibitors; approved drug; clinical study; combination; preclinical study; targeted therapy.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15437
    ≥98.0%, MEK Inhibitor
    MEK